Moreover, for intrahepatic cholangiocarcinoma (ICC), which belong to a type of primary carcinoma of the liver, with FGFR2 gene fusion, sorafenib has a preferable clinical treatment effect (Ying et al., 2019). Here, FGFR2 is linked to hepatocellular carcinoma.